Status:
COMPLETED
Yellow Fever Vaccine in Patients With Rheumatic Diseases
Lead Sponsor:
University of Sao Paulo General Hospital
Conditions:
Systemic Lupus
Rheumatoid Arthritis
Eligibility:
All Genders
2-60 years
Phase:
NA
Brief Summary
According to World Health Organization (WHO), since December 2016, Brazil is showing a significant increase in cases of yellow fever in humans. In view of this, vaccination is suitable for residents a...
Eligibility Criteria
Inclusion
- Rheumatic disease under low immunosuppression (hydroxychloroquine, sulfasalazine or methotrexate plus prednisone up to 7,5mg/day or leflunomide plus prednisone up to 7,5mg/day),
- Resident in high risk área for Yellow Fever
Exclusion
- Active disease
- Primary immunodeficiency
- History of anaphylactic response to vaccine components or egg allergy
- Living outside the risk area
- Do not meet criteria for low immunosuppression
- History of previous immunization with the yellow fever vaccine
- History of live virus vaccine up to 4 weeks before
- Individuals who do not agree to participate in the study and/or whose parents do not agree to participate in the study
Key Trial Info
Start Date :
January 31 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 24 2019
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT03430388
Start Date
January 31 2018
End Date
February 24 2019
Last Update
April 26 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo
São Paulo, São Paulo, Brazil, 05403-000